Combination Therapy
AssigneeAstraZeneca AB
InventorsStephen Robert Wedge, Anderson Joseph Ryan
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises: the administration of ZD6474 in combination with 5-FU; ZD6474 in combination with CPT-11; or ZD6474 in combination with 5-FU and CPT-11.
Claims19
1-7. (canceled)
A pharmaceutical composition comprising
- ZD6474 or a pharmaceutically acceptable salt thereof, and
- at least one selected from the group consisting of 5-FU and CPT-11,
- in association with a pharmaceutically acceptable excipient or carrier.
11-13. (canceled)
A method for the treatment of a cancer in a warm-blooded animal, which comprises administering to said animal in need thereof an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, also known as ZD6474:
- or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:
- a.) 5-FU
- b.) CPT-11;
- or
- c.) 5-FU and CPT-11.
Dependencies are inferred from the claim text.